

Clinical Utilization Management Guidelines – First Quarter, 2017

On March 21, 2017, the Medical Operations Committee for the Government Business Division adopted the following *Clinical Utilization Management (UM) Guidelines*.

The inclusion of procedures on this list does not override state-specific legal prohibitions preauthorization requirements.

Highlighted sections indicate a new or revised guideline. To see the full list of *Clinical UM Guidelines*, visit https://www11.anthem.com/cptsearch_shared.html.

Guideline number	<i>Clinical UM Guidelines name/title</i>
CG-DRUG-01	Off-Label Drug and Approved Orphan Drug Use
CG-DRUG-03	Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis
CG-DRUG-04	Use of Low Molecular Weight Heparin Therapy, Fondaparinux (Arixtra®), and Direct Thrombin Inhibitors in the Outpatient Setting
CG-DRUG-05	Recombinant Erythropoietin Products
CG-DRUG-07	Hepatitis C Pegylated Interferon Antiviral Therapy (Archived 04/05/16)
CG-DRUG-08	Enzyme Replacement Therapy for Gaucher Disease
CG-DRUG-09	Immune Globulin (Ig) Therapy
CG-DRUG-11	Infertility Drugs
CG-DRUG-13	Hepatitis B Interferon Antiviral Therapy
CG-DRUG-15	Gonadotropin Releasing Hormone Analogs
CG-DRUG-16	White Blood Cell Growth Factors
CG-DRUG-19	Progesterone Therapy as a Technique to Prevent Preterm Delivery in High-Risk Women
CG-DRUG-20	Enfuvirtide (Fuzeon)
CG-DRUG-21	Naltrexone (Vivitrol®) Injections for the Treatment of Alcohol and Opioid Dependence
CG-DRUG-24	Repository Corticotropin Injection (H.P. Acthar® Gel)
CG-DRUG-27	Clostridial Collagenase Histolyticum Injection
CG-DRUG-28	Alglucosidase alfa (Lumizyme®, Myozyme®)
CG-DRUG-29	Hyaluronan Injections in the Knee
CG-DRUG-30	Oprelvekin (Neumega)
CG-DRUG-33	Palonosetron (Aloxi®)
CG-DRUG-34	Docetaxel (Docefrez™, Taxotere®)
CG-DRUG-38	Pemetrexed Disodium (Alimta®)
CG-DRUG-40	Bortezomib (Velcade®)
CG-DRUG-41	Zoledronic acid
CG-DRUG-42	Asparagine Specific Enzymes (Asparaginase)
CG-DRUG-43	Natalizumab (Tysabri®)
CG-DRUG-44	Pegloticase (Krystexxa®)
CG-DRUG-45	Octreotide acetate (Sandostatin®; Sandostatin® LAR Depot)
CG-DRUG-46	Fosaprepitant (Emend®)

<https://medproviders.anthem.com/ky>

Anthem Blue Cross and Blue Shield Medicaid is the trade name of Anthem Kentucky Managed Care Plan, Inc., independent licensee of the Blue Cross and Blue Shield Association. ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. AKYPEC-1251-17 September 2017



Guideline number	<i>Clinical UM Guidelines name/title</i>
CG-DRUG-47	Level of Care: Specialty Pharmaceuticals
CG-DRUG-48	Azacitidine (Vidaza [®])
CG-DRUG-49	Doxorubicin Hydrochloride Liposome Injection
CG-DRUG-50	Paclitaxel, protein-bound (Abraxane [®])
CG-DRUG-51	Romidepsin (Istodax [®])
CG-DRUG-52	Temsirolimus (Torisel [®])
CG-DRUG-53	Drug Dosage, Frequency, and Route of Administration
CG-DRUG-54	Agalsidase beta (Fabrazyme [®])
CG-DRUG-55	Elosulfase alfa (Vimizim [®])
CG-DRUG-56	Galsulfase (Naglazyme [®])
CG-DRUG-57	Idurasufase (Elaprase [®])
CG-DRUG-58	Laronidase (Aldurazyme [®])
CG-DRUG-59	Testosterone, Injectable
CG-DRUG-60	Gonadotropin Releasing Hormone Analogs for the Treatment of Oncologic Indications
CG-DRUG-61	Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications
CG-DRUG-62	Fulvestrant (FASLODEX [®])
CG-DRUG-63	Levoleucovorin Calcium (Fusilev [®])
CG-DRUG-64	FDA-Approved Biosimilar Products